Oxcia AB publishes year-end report for 2024. Oxcia’s financial reports are only available in swedish. They can be found Finansiella rapporter – Oxcia and Pressmeddelanden Archives – Oxcia.
For more information contact:
Ulrika Warpman Berglund, CEO, Oxcia AB (publ)
Telephone: +46 (0) 73 270 9605
ulrika.warpmanberglund@oxcia.com
Briefly about Oxcia AB
Oxcia’s aim is to improve and extend lives by developing new innovative treatments based on our unique technology platform, O2-DDR. Oxcia AB is a pioneer in oxidative DNA damage and DNA Damage Response (DDR – the processes the body uses to repair the damage that occurs to DNA) with a focus on developing new safe and effective treatments for patients suffering from diseases caused by cancer or inflammation. Oxcia currently has two O2-DDR lead drug candidates, both with the potential to become first-in-class drugs. OXC-101 is in early clinical development as novel cancer therapy. OXC-201 is developed against idiopathic pulmonary fibrosis, and is in the preclinical phase. The portfolio also includes exploratory projects, e.g in psoriasis.
More information about Oxcia is available at www.oxcia.com